Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COURAGE-ALS open-label extension of reldesemtiv in ALS
NL-OMON53955Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reldesemtiv in amyotrophic lateral sclerosis (ALS), sponsored by Cytokinetics. Primary endpoint: Incidence of adverse events. Started Feb 2023; status: active, not recruiting.
02
Drugs
reldesemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON53955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53955.